Beyond Biometrics: Connecting Behavioral Profiles to Achieve the Right Kind of Weight Loss

Weight-loss medications work only while patients keep taking them. The real goal is staying on medication long enough to achieve meaningful, functional weight loss and sustain it. This webinar explores why that's harder than it sounds: not for the clinical reasons often expected, but rather because of the beliefs and psychology, including the significance of volitional medication use in obesity, that predict who stays engaged and who drops off before seeing the long-term benefits.

For pharma professionals supporting an obesity portfolio, that gap is an important challenge to address. Clinical trials show sustained weight reduction of 15–22% over 72 weeks, but real-world discontinuation can be up to 67% within 12 months. Side effects, cost and access explain only part of that drop-off. Most support programs have no validated way to identify behavioural risk before it impacts success.

Psychological factors, such as confidence, doubt and treatment identity, are increasingly recognised as independent predictors of discontinuation. Underlying motivations and beliefs about treatment, whether rooted in appearance, day-to-day function or long-term health risk, differ from patient to patient. Left unaddressed, these differences can determine whether someone stays on treatment and reaches a functional, lasting outcome. Digital health technology can help keep people engaged and on track.
The featured speakers will discuss findings from a novel study of 1,056 US adults using a GLP-1/GIP medication for weight management, evaluated using the SPUR behavioural framework alongside validated belief and mental-health measures. They'll introduce Kaitality™, Clinical ink's general wellness app, and show how connecting biometrics (weight, body composition and activity), sociometrics (social context and daily environment) and psychometrics (validated psychological drivers of adherence) can generate real-world evidence and support progress toward sustained functional quality weight loss goals.
Register for this webinar to learn how a behavioural profile can help identify adherence risk, personalise patient support and support sustained functional weight loss.

Who Should Attend

This webinar will appeal to pharma medical, marketing and real-world evidence professionals supporting obesity portfolios including:

• Medical Affairs and Outcomes Research / HEOR professionals evaluating real-world evidence strategies for GLP-1 and obesity portfolios
• Digital Health leads (clinical and commercial) assessing behavioral and biometric technology partnerships
• Brand team leads responsible for brand strategy and performance from launch through lifecycle
• Patient Support Program (PSP) leaders looking for predictive, behavioral-driven adherence support to help people meet and maintain their weight loss goals
• Pharma Commercial and Market Research teams tracking the evolving GLP-1 competitive and adherence landscape

What You Will Learn

Attendees will learn:

• How connecting behavioural profiles with objective biometric data can help support programs prioritise outreach before disengagement
• How behavioural and biometric data can inform more personalised patient support
• How behavioural drivers can help explain treatment continuation beyond factors such as side effects, cost and access
• How support programs can move beyond pounds lost toward sustained, functional quality weight loss
• How behavioural insights can inform patient adherence programs, shape real-world evidence strategy or manage GLP-1-related health outcomes

Register free on Xtalks:
https://xtalks.com/webinars/beyond-biometrics-connecting-behavioral-profiles-to-achieve-the-right-kind-of-weight-loss/